VIVA23 Presents Outcomes of Late-breaking Science from Abbot

The second round of late-breaking clinical trials were presented with results from three studies during the Vascular InterVentional Advances Conference, VIVA23, being held Oct. 30-Nov. 2 in Las Vegas, NV. Notably, results from Abbott’s LIFE-BTK randomized clinical trial (RCT) demonstrated that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.

Related Keywords

San Francisco , California , United States , Japan , New Zealand , Marianne Brodmann , Robert Lookstein , Raghu Kolluri , Wynn Las Vegas , Vascular Interventional Advances Conference , Controlled Trial Evaluating , Eluting Resorbable Scaffold , Transcatheter Cardiovascular Therapeutics , Infrapopliteal Artery , New England Journal , Month Results , Rutherford Classification , Trial Thrombosis Predictors , Vascular Interventional Advances ,